Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01609556
Title First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors ImmunoGen, Inc.
Indications

Advanced Solid Tumor

Therapies

Mirvetuximab Soravtansine

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.